Showing 3921-3930 of 10903 results for "".
- Alumis Closes $259 Million Financing to Help Launch Phase 3 Psoriasis Trial for Lead Asset ESK-001https://practicaldermatology.com/news/alumis-closes-259-million-financing-to-help-launch-phase-3-psoriasis-trial-for-lead-asset/2462267/In this year's largest privite biotech fundraise to date, Alumis announced $259 million Series C financing to initiate pivotal phase 3 clinical trials for its lead candidate ESK-001, a highly selective allosteric tyrosine kinase 2 (TYK2) inhibitor, in moderate to severe pl
- Cyndi Lauper to Host New Novartis PsO Podcasthttps://practicaldermatology.com/news/cyndi-lauper-to-host-new-novartis-pso-podcast/2460514/Novartis is launching PsO in the Know, a podcast series hosted by music icon Cyndi Lauper. PsO in the Know will feature a variety of guests, including Chef Aarón Sánchez, actress and New York Times best-selling author La La Anthony, and Emmy
- Botox Hits the Big 3-0https://practicaldermatology.com/news/botox-hits-the-big-3-0/2460184/Botox is turning 30, and Allergan fêted its shining star, Botox Cosmetic, in style at a New York City bash. The event included the debut of Botox Cosmetic’s new packaging and a panel discussion featuring New York City dermatologists Macrene Alexiades-Armenakas, MD, PhD
- L'Oréal Debuts Wearable Electronic UV Monitorhttps://practicaldermatology.com/news/loral-debuts-wearable-electronic-uv-monitor/2458740/Earlier this month at the Consumer Electronics Show, L’Oréal unveiled My UV Patch, a stretchable skin sensor designed to monitor UV exposure and help consumers educate themselves about sun protection. L’Oréal Group’s dermatological skincare brand, La Roche-Posay, i
- Consensus IDs Gaps in Atopic Dermatitis Skin Modelshttps://practicaldermatology.com/news/consensus-ids-gaps-in-atopic-dermatitis-skin-models/2488670/A 2026 expert consensus review published in the Journal of Investigative Dermatology examined the advantages and limitations of human-based in vitro models for atopic dermatitis (AD), identifying opportunities to improve preclinical research and reduce reliance on animal models. R
- Study Finds Racial Variation in Keloid Treatmenthttps://practicaldermatology.com/news/study-finds-racial-variation-in-keloid-treatment/2488178/An electronic health record analysis found differences in how keloids are treated across racial groups. In a Letter to the Editor published in the Journal of Drugs in Dermatology, investigators evaluated treatment patterns among adults with keloids using the TriNetX Research Netwo
- Researchers Recommend Refined Trial Design for Pediatric Vitiligo JAK Studieshttps://practicaldermatology.com/news/letter-highlights-trial-design-considerations-in-pediatric-vitiligo/2487858/Correspondence in the Journal of the American Academy of Dermatology asked for caution when interpreting findings from a recent trial evaluating oral Janus kinase (JAK) inhibitors in combination with 308-nm excimer laser th
- Study: One-Third of Pemphigus Cases Deviate From Classic Desmoglein Compensation Modelhttps://practicaldermatology.com/news/study-one-third-of-pemphigus-cases-deviate-from-classic-desmoglein-compensation-model/2487700/
- Laser Speckle Imaging Shows Promise for Objective Rosacea Assessment: Analysishttps://practicaldermatology.com/news/laser-speckle-imaging-shows-promise-for-objective-rosacea-assessment-analysis/2487680/
- Letter Questions Strength of Evidence Linking Hair Relaxers to Uterine Cancerhttps://practicaldermatology.com/news/letter-questions-strength-of-evidence-linking-hair-relaxers-to-uterine-cancer/2487618/A recently published Letter to the Editor in the Journal of Drugs in Dermatology urged clinicians to interpret the growing body of research examining chemical hair relaxers and uterine cancer with caution, arguing that important methodological limitations prevent current evidence from es